Galderma’s relabotulinumtoxinA FDA setback shifts attention to manufacturing readiness
Discover why FDA manufacturing concerns have delayed Galderma’s relabotulinumtoxinA approval and what the company must resolve next.
Pharma & Biotech
Pharma & Biotech
Merz Therapeutics tests the long game in neurorehabilitation with XEOMIN data
Spasticity care is not one injection cycle. Merz Therapeutics is pushing XEOMIN data toward durability, dosing flexibility and patient goals.
Pharma & Biotech
AbbVie’s fast-acting Botox rival just hit a regulatory wall, but not where investors feared
AbbVie’s TrenibotulinumtoxinE faces an FDA manufacturing CRL. Find out what this means for approval, aesthetics and neurotoxins.
Pharma & Biotech
What AEON Biopharma Inc.’s analytical strategy reveals about the future of botulinum toxin biosimilars
AEON Biopharma advances ABP-450 biosimilar strategy. Discover what this means for BOTOX competition and future complex biologics markets.